MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts


 


NEW YORK, Oct. 21, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:


MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts
http://www.reportlinker.com/p01698847/MediPoint-Drug-Eluting-Balloons---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts


Summary

GlobalData has released its medical devices report, "MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts". The report provides in-depth insight into the use of DEB in the European Union (EU) for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in the five major EU countries including France, Germany, Italy, Spain and the UK was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications. The EU sales expectations are discussed through careful analysis of adoption patterns of using DEB in clinical practice.

Clients can use this report to better understand the Scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData's team of industry experts.


Scope

- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in the EU from 2010-2012 and forecast for seven years to 2019.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in the five major EU countries covered in the report, and implications of the drug-eluting balloon market.
- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.
- Analysis of the current and future market competition in the EU drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.


Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DEB market in the EU.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EU DEB market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the EU DEB market by disease and indication from 2010-2019.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents


Table of Contents
8
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 27
3 Disease Overview 28
3.1 Overview 28
3.1.1 Coronary Artery Disease 28
3.1.2 Peripheral Artery Disease 28
3.2 Anatomy and Physiology 29
3.2.1 Coronary Arteries 29
3.2.2 Peripheral Arteries of the Lower Extremity 30
3.3 Pathophysiology 32
3.3.1 Coronary Artery Disease 32
3.3.2 Peripheral Artery Disease 33
3.4 Clinical Presentation 34
3.4.1 Symptoms 34
3.4.2 Risk Factors 37
3.4.3 Disease Classification 38
3.4.4 Diagnosis 39
3.4.5 Clinical Outcomes 42
3.5 Epidemiology 75
3.5.1 Coronary Artery Disease 75
3.5.2 Peripheral Artery Disease 77
3.6 Economic Impact of Coronary and Peripheral Artery Disease 81
3.6.1 Cost of Coronary Artery Disease 81
3.6.2 Cost of Peripheral Artery Disease 82
3.6.3 Treatment Costs of Coronary and Peripheral Artery Disease 83
4 Competitive Assessment 86
4.1 Overview 86
4.2 Product Profiles by Company 88
4.2.1 Aachen Resonance 89
4.2.2 B. Braun 91
4.2.3 Biotronik 98
4.2.4 Blue Medical 101
4.2.5 Cardionovum 107
4.2.6 C.R. Bard 112
4.2.7 Concept Medical Research 118
4.2.8 Cook Medical 122
4.2.9 Eurocor 124
4.2.10 Medrad (Bayer Healthcare) 139
4.2.11 Medtronic 141
4.2.12 Minvasys 149
5 Unmet Needs 152
5.1 Need for Better Clinical Outcomes in Specific Lesions 152
5.1.1 Chronic Total Occlusions 152
5.1.2 Small-Vessel Coronary Lesions 153
5.1.3 Long Lesions 153
5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 154
5.1.5 Bifurcation Lesions 154
5.2 Need for Better Revascularization of the Femoropopliteal Artery 155
5.3 Difficulty in Treating the Infrapopliteal Artery 157
5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 158
5.5 Addressing Challenges of Stenting 160
5.5.1 Risk of Post-Procedural Complications 160
5.5.2 In-Stent Restenosis 162
5.5.3 Stent-In-Stent Procedures 163
5.5.4 Prolonged Dual Antiplatelet Therapy 164
5.5.5 Lack of Homogenous Drug Distribution 165
5.5.6 Delayed Healing 165
5.5.7 Stent Fracture 166
5.5.8 Negative Vessel Remodeling 167
5.5.9 Long-Term Vessel Patency 168
5.6 Need for Effective Therapy for Specific Patient Populations 168
5.7 Lack of Clinical Data 169
5.8 Addressing the Complications of Bypass Surgery 169
5.9 Need to Improve Medical Therapy 170
5.10 Comparative Studies on Exercise Therapy for PAD 171
6 Pipeline Products 172
6.1 Overview 172
6.2 Pipeline by Stage of Development 173
6.3 Pipeline Product Profiles 175
6.3.1 NF-?B Decoy Oligo DEB 175
6.3.2 Drug-Coated AngioSculpt 177
6.3.3 BioPath 180
6.3.4 BioStream 181
6.3.5 Boston Scientific Drug-Coated Balloon 182
6.3.6 Coroflex DEBlue 183
6.3.7 Covidien Drug-Coated Balloon 185
6.3.8 DSM Biomedical and Caliber Therapeutics DEB 187
6.3.9 Elixir Medical Corporation DCB 188
6.3.10 LifeTech Scientific Corporation DEB 188
6.3.11 Micell Technologies Drug-Coated Balloon 188
6.3.12 Drug-Coated Chocolate DEB 190
6.3.13 Passeo-18 Lux 192
6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 193
6.3.15 WOMBAT DCB 194
7 Clinical Trial Analysis 196
7.1 Overview 196
7.2 Clinical Trials to Watch 196
7.2.1 Drug-Eluting Balloons 196
7.2.2 Vascular Stents 210
8 Industry Overview 215
8.1 Procedure Trends 215
8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 215
8.1.2 Coronary Artery Disease 216
8.1.3 Peripheral Artery Disease 217
8.2 Physician Decision-Making Process 219
8.3 Market Access 221
8.3.1 Regulatory Process 222
8.3.2 Adoption 223
8.3.3 Reimbursement Trends in the EU 226
8.4 Regulatory Issues/Recalls 230
8.4.1 Regulatory Issues 230
8.4.2 Product Recalls 231
8.5 Mergers and Acquisitions/Partnerships 231
8.5.1 Biosensors International and Eurocor 231
8.5.2 Boston Scientific Corporation and Guidant Corporation 232
8.5.3 Covidien and ev3, CV Ingenuity 232
8.5.4 C.R. Bard and Lutonix 233
8.5.5 DSM Biomedical and Caliber Therapeutics 233
8.5.6 Micell Technologies and Maxcor Lifescience 234
8.5.7 Medrad and Bayer 234
8.5.8 Medtronic and Invatec 235
9 Current and Future Players 236
9.1 Overview 236
9.2 Trends in Corporate Strategy 237
9.3 Company Profiles 240
9.3.1 Aachen Resonance 240
9.3.2 AnGes MG 241
9.3.3 AngioScore 243
9.3.4 AVIDAL Vascular 245
9.3.5 B. Braun 247
9.3.6 Biosensors International 249
9.3.7 Biotronik 251
9.3.8 Blue Medical 253
9.3.9 Boston Scientific Corporation 255
9.3.10 Caliber Therapeutics 257
9.3.11 Cardionovum 259
9.3.12 Concept Medical Research 261
9.3.13 Cook Medical 263
9.3.14 Covidien 265
9.3.15 C.R. Bard 267
9.3.16 DSM Biomedical 269
9.3.17 Elixir Medical Corporation 271
9.3.18 Eurocor 273
9.3.19 LifeTech Scientific Corporation 275
9.3.20 Medtronic 277
9.3.21 Micell Technologies 279
9.3.22 Minvasys 280
9.3.23 TriReme Medical 282
9.3.24 Vascular Nanotransfer Technologies 284
10 Market Drivers, Opportunities, Barriers and Substitutes 286
10.1 Market Drivers 286
10.1.1 Rising Prevalence of Disease 287
10.1.2 Viable Treatment for Select Indications 288
10.1.3 No Metal Left Behind 293
10.1.4 Avoid Stent-in-Stent Procedures 294
10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 295
10.1.6 Enhanced Vessel Healing and Better Patency 295
10.1.7 Technical Feasibility of Future Interventions 296
10.1.8 DEB as an Adjunctive Therapy 297
10.1.9 Limb Amputation 297
10.1.10 Cost Savings 298
10.1.11 Availability of Long-Term and Cost-Effective Data 299
10.1.12 Launch of DEB in the US 299
10.2 Opportunities 300
10.2.1 Improve DEB Design 300
10.2.2 DEB Hybrid Systems (DEB + Stent) 304
10.2.3 Target Indications Where Stenting is Not Satisfactory 304
10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 307
10.2.5 Target Challenging Patient Populations 309
10.2.6 Launch DEB in the Japanese Market 310
10.2.7 Emerging Markets 310
10.3 Market Barriers 311
10.3.1 Slow Adoption 311
10.3.2 High Selling Prices 315
10.3.3 Lack of Reimbursement 316
10.3.4 US FDA Regulatory Challenges 317
10.3.5 Healthcare Cost-Cutting and Reimbursement 318
10.3.6 Availability of Venture Capital 319
10.3.7 Medical Device Excise Tax 320
10.4 Market Substitutes 320
10.4.1 Vascular Stents 320
10.4.2 Liquid Drug Delivery Catheter 324
11 Drug-Eluting Balloon Market Analysis 327
11.1 Global Market Overview 327
11.2 Market Analysis by Type of Disease 328
11.2.1 Coronary Artery Disease 328
11.2.2 Peripheral Artery Disease in the Lower Extremity 329
11.3 Market Distribution by Indication 332
11.4 Primary Versus Adjunctive Therapy 334
11.5 Comparative Market Analysis 336
11.5.1 Coronary Artery Disease 336
11.5.2 Peripheral Artery Disease in the Lower Extremity 338
12 Country Outlooks & Forecasts 340
12.1 Overview 340
12.2 France 342
12.2.1 Overview 342
12.2.2 Market Analysis 342
12.3 Germany 344
12.3.1 Overview 344
12.3.2 Market Analysis 344
12.4 Italy 348
12.4.1 Overview 348
12.4.2 Market Analysis 348
12.5 Spain 351
12.5.1 Overview 351
12.5.2 Market Analysis 351
12.6 United Kingdom 353
12.6.1 Overview 353
12.6.2 Market Analysis 353
13 Appendix 356
13.1 Bibliography 356
13.2 Abbreviations 382
13.3 Report Methodology 386
13.3.1 Overview 386
13.3.2 Coverage 386
13.3.3 Secondary Research 386
13.3.4 Forecasting Methodology 387
13.4 Physicians and Specialists Included in this Study 389
13.5 Physician Survey 392
13.6 About the Authors 393
13.6.1 Analysts 393
13.6.2 Global Head of Healthcare 394
13.7 About MediPoint 395
13.8 About GlobalData 395
13.9 Disclaimer 395




List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 36
Table 2: Risk Factors Associated with CAD and PAD 37
Table 3: Types of Atherosclerotic Lesions 39
Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 44
Table 5: TASC II Classification of Iliac Artery Lesions 45
Table 6: TASC II Classification of Femoropopliteal Artery Lesions 46
Table 7: TASC II Classification of Infrapopliteal Artery Lesions 47
Table 8: Types of Coronary Artery Bypass Grafting 58
Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery 59
Table 10: Indications for Using Drug-Eluting Balloons 63
Table 11: Drug-Eluting Balloon Coating Characteristics 65
Table 12: Drugs Incorporated Into Drug-Eluting Stents 68
Table 13: Types of Lesions Treated Using Atherectomy 71
Table 14: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010-2019 76
Table 15: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010-2019 78
Table 16: Direct and Indirect Healthcare Costs 81
Table 17: Healthcare Expenditures ($bn) for CAD in the Five Major EU Countries, 2006 82
Table 18: Healthcare Expenditures ($bn) for PAD in the EU 82
Table 19: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2011-2019 ($US) 84
Table 20: EU DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 86
Table 21: Marketed DEB Products 88
Table 22: Elutax SV Product Portfolio 89
Table 23: Elutax SV SWOT Analysis, 2013 91
Table 24: SeQuent Please Product Portfolio 92
Table 25: SeQuent Please SWOT Analysis, 2013 97
Table 26: Pantera Lux Product Portfolio 98
Table 27: Pantera Lux SWOT Analysis, 2013 100
Table 28: Pioneer Product Portfolio 101
Table 29: Pioneer SWOT Analysis, 2013 103
Table 30: Protégé Product Portfolio 104
Table 31: Protégé SWOT Analysis, 2013 107
Table 32: Restore DEB Product Portfolio 108
Table 33: Restore DEB SWOT Analysis, 2013 109
Table 34: Legflow DEB Product Portfolio 110
Table 35: Legflow DEB SWOT Analysis, 2013 112
Table 36: Lutonix Product Portfolio 113
Table 37: Lutonix SWOT Analysis, 2013 118
Table 38: Magic Touch Product Portfolio 119
Table 39: Magic Touch SWOT Analysis, 2013 121
Table 40: Advance 18 PTX Product Portfolio 122
Table 41: Advance 18 PTX SWOT Analysis, 2013 124
Table 42: Dior Product Portfolio 125
Table 43: Dior SWOT Analysis, 2013 131
Table 44: Freeway Family of DEB Product Portfolio 132
Table 45: Freeway Family of DEB SWOT Analysis, 2013 135
Table 46: Magical Product Portfolio 136
Table 47: Magical SWOT Analysis, 2013 138
Table 48: Cotavance Product Portfolio 139
Table 49: Cotavance SWOT Analysis, 2013 141
Table 50: IN.PACT Family DEB Product Portfolio 142
Table 51: IN.PACT SWOT Analysis, 2013 149
Table 52: Danubio Product Portfolio 150
Table 53: Danubio SWOT Analysis, 2013 151
Table 54: Global DEB Pipeline Products 174
Table 55: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 177
Table 56: AngioSculpt SWOT Analysis, 2013 179
Table 57: BioPath SWOT Analysis, 2013 181
Table 58: BioStream SWOT Analysis, 2013 182
Table 59: Boston Scientific DEB SWOT Analysis, 2013 183
Table 60: Coroflex DEBlue SWOT Analysis, 2013 185
Table 61: Covidien DCB SWOT Analysis, 2013 187
Table 62: Micell Technologies' DCB SWOT Analysis, 2013 189
Table 63: Drug-Coated Chocolate DEB SWOT Analysis, 2013 191
Table 64: Passeo-18 Lux SWOT Analysis, 2013 193
Table 65: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 194
Table 66: WOMBAT DCB SWOT Analysis, 2013 195
Table 67: Aachen Resonance Company Profile 240
Table 68: Aachen Resonance, Marketed DEB Product 241
Table 69: Aachen Resonance SWOT Analysis, 2013 241
Table 70: AnGes MG Company Profile 242
Table 71: AnGes MG, Pipeline DEB Product 243
Table 72: AnGes MG SWOT Analysis, 2013 243
Table 73: AngioScore Company Profile 244
Table 74: AngioScore, Pipeline DEB Product 244
Table 75: AngioScore SWOT Analysis, 2013 245
Table 76: AVIDAL Vascular Company Profile 245
Table 77: AVIDAL Vascular, Pipeline DEB Product 246
Table 78: AVIDAL Vascular SWOT Analysis, 2013 247
Table 79: B. Braun Company Profile 247
Table 80: B. Braun, Marketed and Pipeline DEB Products 248
Table 81: B. Braun SWOT Analysis, 2013 249
Table 82: Biosensors International Company Profile 250
Table 83: Biosensors International, Pipeline DEB Products 250
Table 84: Biosensors International SWOT Analysis, 2013 251
Table 85: Biotronik Company Profile 252
Table 86: Biotronik, Marketed and Pipeline DEB Products 252
Table 87: Biotronik SWOT Analysis, 2013 253
Table 88: Blue Medical Company Profile 254
Table 89: Blue Medical, Marketed DEB Products 255
Table 90: Blue Medical SWOT Analysis, 2013 255
Table 91: Boston Scientific Corporation Company Profile 256
Table 92: Boston Scientific Corporation, Pipeline DEB Product 256
Table 93: Boston Scientific Corporation SWOT Analysis, 2013 257
Table 94: Caliber Therapeutics Company Profile 257
Table 95: Caliber Therapeutcs, Pipeline DEB Product 258
Table 96: Caliber Therapeutics SWOT Analysis, 2013 259
Table 97: Cardionovum Company Profile 259
Table 98: Cardionovum, Marketed DEB Products 260
Table 99: Cardionovum SWOT Analysis, 2013 261
Table 100: Concept Medical Research Company Profile 261
Table 101: Concept Medical Research, Marketed DEB Product 262
Table 102: Concept Medical Research SWOT Analysis, 2013 263
Table 103: Cook Medical Company Profile 263
Table 104: Cook Medical, Marketed DEB Product 264
Table 105: Cook Medical SWOT Analysis, 2013 265
Table 106: Covidien Company Profile 266
Table 107: Covidien, Pipeline DEB Product 266
Table 108: Covidien SWOT Analysis, 2013 267
Table 109: C.R. Bard Company Profile 267
Table 110: C.R. Bard, Marketed DEB Products 268
Table 111: C.R. Bard SWOT Analysis, 2013 269
Table 112: DSM Biomedical Company Profile 270
Table 113: DSM Biomedical, Pipeline DEB Product 270
Table 114: DSM Biomedical SWOT Analysis, 2013 271
Table 115: Elixir Medical Corporation Company Profile 271
Table 116: Elixir Medical Corporation, Pipeline DEB Product 272
Table 117: Elixir Medical Corporation SWOT Analysis, 2013 272
Table 118: Eurocor Company Profile 273
Table 119: Eurocor, Marketed DEB Products 274
Table 120: Eurocor SWOT Analysis, 2013 274
Table 121: LifeTech Scientific Corporation Company Profile 275
Table 122: LifeTech Scientific, Pipeline DEB Product 276
Table 123: LifeTech Scientific SWOT Analysis, 2013 276
Table 124: Medtronic Company Profile 277
Table 125: Medtronic, Marketed DEB Products 278
Table 126: Medtronic SWOT Analysis, 2013 278
Table 127: Micell Technologies Company Profile 279
Table 128: Micell Technologies, Pipeline DEB Product 280
Table 129: Micell Technologies SWOT Analysis, 2013 280
Table 130: Minvasys Company Profile 281
Table 131: Minvasys, Marketed DEB Product 281
Table 132: Minvasys SWOT Analysis, 2013 282
Table 133: TriReme Medical Company Profile 282
Table 134: TriReme Medical, Pipeline DEB Product 283
Table 135: TriReme Medical SWOT Analysis, 2013 284
Table 136: Vascular Nanotransfer Technologies Company Profile 284
Table 137: Vascular Nanotransfer Technologies, Pipeline DEB Product 285
Table 138: Vascular Nanotransfer Technologies SWOT Analysis, 2013 285
Table 139: EU Coronary and Peripheral DEB Market ($m) Forecast, 2010-2019 328
Table 140: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 329
Table 141: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, EU, 2012 and 2018 (N=56) 334
Table 142: DEB Sales ($m) Forecast for France, 2010-2019 342
Table 143: DEB Sales ($m) Forecast for Germany, 2010-2019 345
Table 144: DEB Sales ($m) Forecast for Italy, 2010-2019 348
Table 145: DEB Sales ($m) Forecast for Spain, 2010-2019 352
Table 146: DEB Sales ($m) Forecast for UK, 2010-2019 354
Table 147: Physicians Surveyed, By Country 392

1.2 List of Figures
Figure 1: Coronary Arteries of the Human Heart 29
Figure 2: Peripheral Arteries of the Lower Extremity 30
Figure 3: Pathophysiology of Coronary Artery Disease 32
Figure 4: Pathophysiology of Peripheral Artery Disease 33
Figure 5: Treatment Modalities - Coronary Artery Disease 49
Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, EU, 2012 and 2019 (N=32) 50
Figure 7: Treatment Modalities - Peripheral Artery Disease 51
Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 52
Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 53
Figure 10: Drug-Eluting Balloon 61
Figure 11: Types of Stents Used to Treat CAD and PAD 67
Figure 12: Bare Metal Stent 67
Figure 13: Drug-Eluting Stent 68
Figure 14: Covered Stents 69
Figure 15: Bioabsorbable Stent - Remedy 70
Figure 16: Types of Atherectomy 72
Figure 17: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010-2019 76
Figure 18: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010-2019 79
Figure 19: Healthcare Expenditures ($bn) for PAD in the EU 83
Figure 20: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010-2019 ($US) 85
Figure 21: EU DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 87
Figure 22: Image of the Protégé DEB 105
Figure 23: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, EU, 2012 and 2018 (N=56) 159
Figure 24: Percent of CAD and PAD Patients with Thrombosis After Stenting, EU, 2012 and 2018 (N=56) 161
Figure 25: Percent of CAD and PAD Patients with ISR, EU, 2012 and 2018 (N=56) 162
Figure 26: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, EU, 2012 and 2018 (N=56) 164
Figure 27: Percent of CAD and PAD Patients with Stent Fracture, EU, 2012 and 2018 (N=56) 167
Figure 28: Global DEB Pipeline Products by Stage of Development, 2013 173
Figure 29: AngioSculpt Scoring Balloon Expansion Profile 178
Figure 30: Drug-Coated Chocolate DEB 190
Figure 31: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, EU*, 2010-2019 217
Figure 32: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 218
Figure 33: Population (? 65 years) with PAD Receiving DEB Angioplasty in the Peripheral Arteries in the Lower Extremity, EU*, 2010-2019 219
Figure 34: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 236
Figure 35: DEB Market for Each Type of Disease, Company Share (%), 2012 238
Figure 36: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 301
Figure 37: EU DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 327
Figure 38: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010-2019 330
Figure 39: EU DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 331
Figure 40: EU DEB Market Distribution (%) by Indication, 2012 and 2018 (N=56) 333
Figure 41: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=32) 337
Figure 42: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=24) 338
Figure 43: EU DEB Market Revenue ($m), 2012 and 2019 341
Figure 44: French DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 343
Figure 45: German DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 345
Figure 46: Italian DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 349
Figure 47: Spanish DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 352
Figure 48: UK DEB Market ($m) for Coronary and Peripheral Applications, 2010-2019 355



To order this report: MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts
http://www.reportlinker.com/p01698847/MediPoint-Drug-Eluting-Balloons---EU-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology




__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.